Subcellular location of antitumor tripeptide-tyroserleutide in human hepatocellular carcinoma cells
Xu Jian1, Zheng Fu, Yanling Zhang
1Central Laboratory of General Hospital of Tianjin Medical University;
Abstract:
Tyroserleutide (YSL) is a tripeptide compound that exhibits potent antitumor activity in human tumor xenografts and tumor cell lines. However, the target of YSL on which it exerts its antitumor activity has yet to be identified. Therefore, our study aimed to investigate the subcellular location of YSL in BEL-7402 human hepatocellular carcinoma cells. Using methods of fluorescent tracing and confocal colocalization, we provide evidence that when BEL-7402 cells are treated with YSL, YSL is distributed in the cytoplasm and colocalized with the mitochondria of cancer cells. Furthermore, we observed the effect of YSL on the isolated mitochondria. Using fluorescence spectrophotometry to monitor the Δψ collapse of mitochondria isolated from BEL-7402 cells by reversion of the quenching of tetramethylrhodamine methyl ester (TMRM), we found that the isolated mitochondria reversed the quenching of the fluorescence in the solution containing TMRM and YSL. This indicates that YSL decreases the Δψ of the isolated mitochondria. Another photometry method was used to observe the effect on mitochondrial swelling when YSL acted directly on the isolated mitochondria. We reveal that YSL directly causes mitochondrial swelling in 60 min. In conclusion, this study encloses a preliminary facet of the pharmacological target of YSL, and we speculate that YSL may act directly on the mitochondria to exert its antitumor activity.
Insights
Tyroserleutide (YSL), a novel antitumor compound, targets cancer cell mitochondria. This study reveals YSL localizes to mitochondria and directly induces mitochondrial dysfunction, suggesting a novel mechanism for its anti-cancer effects.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Tyroserleutide (YSL) is a tripeptide with demonstrated antitumor activity.
- The specific molecular target and mechanism of YSL's action remain unidentified.
Purpose of the Study:
- To determine the subcellular localization of Tyroserleutide (YSL) in BEL-7402 human hepatocellular carcinoma cells.
- To investigate the direct effects of YSL on isolated mitochondria.
Main Methods:
- Fluorescent tracing and confocal colocalization to track YSL.
- Spectrophotometry to assess mitochondrial membrane potential (Δψ) using tetramethylrhodamine methyl ester (TMRM).
- Photometry to evaluate mitochondrial swelling.
Main Results:
- YSL was found to distribute within the cytoplasm and colocalize with mitochondria in BEL-7402 cells.
- YSL treatment led to a decrease in the mitochondrial membrane potential (Δψ) of isolated mitochondria.
- YSL directly induced mitochondrial swelling within 60 minutes.
Conclusions:
- This study provides preliminary evidence that mitochondria are a direct pharmacological target of YSL.
- YSL may exert its antitumor activity by directly impacting mitochondrial function and integrity.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
